# GLP-1 Medications Help Sustain Lower Calorie Intake Beyond One Year
GLP-1 receptor agonists like Ozempic and Wegovy help people maintain reduced calorie intake for over a year, according to recent research. These medications work by regulating appetite hormones, making patients feel fuller longer and less interested in food.
The finding matters for parents watching their children or teens struggle with weight management. These drugs were originally developed for type 2 diabetes but now treat obesity in both adults and adolescents. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) represent the most studied options in this class.
Research shows the appetite-suppressing effects persist beyond 12 months, which addresses a core challenge in weight management. Most diets fail because people regain hunger and return to old eating patterns. GLP-1s appear to sustain behavioral changes by continuing to reduce appetite signals in the brain.
The sustained calorie reduction translates to ongoing weight loss or weight maintenance, which helps prevent yo-yo dieting cycles that stress growing bodies.
Parents considering these medications for teenagers should know that the American Academy of Pediatrics now recognizes GLP-1s as an option for adolescents with obesity when lifestyle changes alone don't work. However, these medications require medical supervision and aren't first-line treatments. Lifestyle modification through balanced nutrition and regular physical activity remain the foundation.
Side effects like nausea, constipation, and vomiting occur in some users but often improve over time. The drugs also cost hundreds of dollars monthly, making access a real barrier for many families.
The long-term safety profile in young people is still emerging. Children metabolize medications differently than adults, and these drugs haven't been used in pediatric populations long enough